Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping.

Pathobiology : journal of immunopathology, molecular and cellular biology·2021
Same author

Molecular pathology of urothelial carcinoma.

Human pathology·2021
Same author

Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now.

Translational andrology and urology·2021
Same author

Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.

Translational andrology and urology·2021
Same author

Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.

Translational andrology and urology·2021
Same author

Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?

Translational andrology and urology·2021

Related Experiment Video

Updated: Mar 26, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Emerging Immunotargets in Bladder Cancer.

Francesco Massari1, Chiara Ciccarese, Nuno Vau

  • 1Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale L.A. Scuro 10, 37124 Verona, Italy. fmassari79@gmail.com.

Current Drug Targets
|February 5, 2016
PubMed
Summary
This summary is machine-generated.

Systemic bladder cancer treatment options are limited, with chemotherapy showing modest results and targeted therapies proving ineffective. Immunotherapy, particularly PD1/PD-L1 pathway inhibition, offers a promising new direction for future treatments.

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K

Related Experiment Videos

Last Updated: Mar 26, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Systemic therapy for bladder cancer has been largely unchanged for decades, relying heavily on chemotherapy.
  • Chemotherapy has reached its therapeutic limit, often with significant toxicity.
  • Targeted therapies have shown limited efficacy in bladder cancer.

Purpose of the Study:

  • To provide an overview of the current landscape of bladder cancer immunotherapy.
  • To highlight the potential of novel immunotherapeutic strategies.
  • To discuss the future of systemic treatment for bladder cancer.

Main Methods:

  • Review of current literature on bladder cancer systemic therapy.
  • Analysis of the efficacy and toxicity of chemotherapy and targeted therapies.
  • Evaluation of emerging immunotherapy approaches, including checkpoint inhibition and fusion proteins.

Main Results:

  • Chemotherapy offers limited benefit and considerable toxicity in bladder cancer.
  • Targeted therapies have not proven effective for bladder cancer.
  • Immunotherapy, specifically PD1/PD-L1 pathway inhibition, demonstrates significant promise.
  • Other immunotherapies like fusion proteins are under investigation.

Conclusions:

  • Immunotherapy represents the most promising future avenue for systemic bladder cancer treatment.
  • PD1/PD-L1 pathway inhibitors are expected to play a major role.
  • Further research into novel immunotherapy strategies is warranted.